




The relative strengths and weaknesses of Provectus Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Provectus Biopharmaceuticals INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 4.1% points. The greatest weakness of Provectus Biopharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 186% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	977
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,975
Liabilities, Non-Current	0
Other Assets	25
Other Compr. Net Income	-0.58
Other Expenses	0
Other Liabilities	0
Other Net Income	-230
Other Revenues	617
Property and Equipment	4.9
Research and Development	1,999
Selling, General and Administrative Expense	3,150

Output Variable	Value in 1000 USD
Assets	1,006
Liabilities	6,975
Expenses	5,150
Revenues	617
Stockholders Equity	-5,969
Net Income	-4,762
Comprehensive Net Income	-4,762
BaseVar	6,989
ECR before LimitedLiability	-445%
Economic Capital Ratio	29%